The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study is a parallel group, single blind, randomized controlled trial. Patients with
pulmonary hypertension who met the inclusion criteria and planned to undergo elective cardiac
surgery under cardiopulmonary bypass from July 1, 2022 to December 1, 2024 in the Department
of cardiac surgery of the First Affiliated Hospital of Shandong First Medical University were
selected. After removing the aortic blocking forceps, the experimental group immediately
injected the test drug (pituitrin 0.04u/ (kg ยท h)) intravenously, The control group was
immediately injected with the corresponding dose of normal saline by intravenous pump. The
main outcome was the composite endpoint of all-cause mortality 30 days after operation or
common complications after cardiac surgery (stroke, requiring mechanical ventilation for more
than 48 hours, deep sternal wound infection, cardiac reoperation, extracorporeal membrane
oxygenation, atrial fibrillation or acute renal injury).